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During the metastatic process, breast cancer cells leave 
the original (primary) tumor site and migrate to other 
parts of the body, often bones or lungs, via the blood-
stream or the lymphatic system. Breast cancer metastases 
are primarily responsible for morbidity associated with 
this tumor type [1]. Th  e biological events involved in 
invasion and metastasis of breast cancer cells are fairly 
well understood, but very little is known about the 
genomic changes that occur during this process. Assess-
ing whether the primary tumor and its corresponding 
metastasis share the same genetic alterations would be of 
utmost relevance to predict whether therapeutic strate-
gies targeting oncogenic events found in primary lesions 
can also be eﬀ  ective on metastatic sites.
In a recent paper, Shah and colleagues [2] used whole-
genome high-throughput sequencing to compare the 
genetic drift of an estrogen receptor-α-positive 
meta  static lobular breast tumor with that of the 
corresponding primary tumor from which it origi  nated 
and that was surgically removed 9 years earlier.
Massive parallel paired-end sequencing of the genome 
and transcriptome of the metastatic lesion led to the 
identiﬁ  cation of multiple genetic aberrations, including 
single-nucleotide variants (SNVs), insertions/deletions, 
gene fusions, translocations, inversions, and copy number 
alterations. Alternative splicing, biased biallelic expres-
sion, and RNA editing changes were also assessed. 
Comparison of the sequence of tumor and normal DNA 
samples led to the identiﬁ  cation of somatic changes. Th  e 
prevalent genetic alterations were SNVs (32 non-
synonymous coding point mutations), whereas a handful 
were gene copy number gains. Interestingly, somatic 
genomic rearrangements, such as translocations, inver-
sions, or fusions, were not identiﬁ  ed. Th  is is somewhat 
surprising if we consider that in other cancer types, such 
as prostate cancer [3] and lung cancer [4], gene fusions 
have been detected by the use of the same technology, 
and these genetic rearrangements are currently con-
sidered among the prevalent genetic events in prostate 
tumors. As the analysis was performed on a single 
specimen, additional breast tumor samples would be 
required to verify whether this is a tissue-speciﬁ  c or a 
patient-speciﬁ   c pattern. Moreover, none of the 32 
mutated genes was listed as a CAN breast gene in a 
previous analysis performed on estrogen receptor-
positive breast tumors [5]. Eleven mutated genes were 
also present in the current release of the Catalogue of 
Somatic Mutations in Cancer (COSMIC) [6]. However, 
the changes occur at positions diﬀ   erent from those 
previously identiﬁ  ed.
Th  e most relevant aspect of the analysis is the 
comparison of the somatic changes found in the 
metastasis with those present in the primary tumor. Only 
11 of the 30 evaluated mutations were detected in the 
DNA of the primary tumor. Th   ese results suggest that, at 
least in this patient, considerable genetic evolution 
occurred in the metastatic process. It is tempting to 
speculate that some of the metastasis-speciﬁ  c mutations 
could be associated with the acquisition of invasive 
properties of breast cancer cells. However, this 
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Therapeutic choices for metastatic tumors are, 
in most cases, based upon the histological and 
molecular analysis of the corresponding primary 
tumor. Understanding whether and to what extent 
the genomic landscape of metastasis diff  ers from 
the tumors from which they originated is critical yet 
largely unknown. A recent report tackled this key 
issue by comparing the genomic and transcriptional 
profi  le of a metastatic lobular breast tumor with that 
of the primary tumor surgically removed 9 years 
earlier. The extent of the diff  erences suggests a high 
degree of mutational heterogeneity between primary 
and metastatic lesions and indicates that signifi  cant 
evolution occurs during breast cancer progression.
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© 2010 BioMed Central Ltdconclu  sion cannot be deﬁ  nitively drawn as the patient 
received both radiotherapy and chemotherapy, which are 
known to aﬀ  ect the genetic milieu of cancer cells [7].
Th   e authors also exploited deviation from the 
theoretical ratio of 0.5 for a heterozygous allele to assess 
the frequencies of the somatic changes between the 
primary and metastatic lesions. Th  e somatic mutations 
identiﬁ  ed in the primary tumor showed three patterns of 
abundance: prevalent, rare, and undetectable. Notably, of 
the 11 shared somatic mutations, only 5 were prevalent 
in the primary tumor (frequency of more than 20% for 
heterozygous variants), whereas 6 were present at lower 
frequencies (1% to 13%). On the other hand, all of them 
were found at prevalent frequencies in the metastatic 
site. Th  ese data are consistent with the expansion of a 
single clone that left the heterogeneous primary site and 
homed to generate the distant meta  stasis. Interestingly, 
the metastatic tumor looks genetically less heterogeneous 
compared with the primary tumor, suggesting that a strong 
selective pressure at the ectopic site likely prevented 
further genetic heterogeneity from developing during the 
metastatic growth.
Th  is work raises a few key questions: to what extent 
does the genetic proﬁ  le of the primary tumor (often the 
only one available) reﬂ   ect that of the corresponding 
metastases? Second, would therapies designed to target 
the genetic lesions found in the primary tumor be eﬀ  ec-
tive on the metastasis? And would molecular analysis of 
the metastatic site be useful to guide thera  peutic choices? 
For example, in this particular patient, the molecular 
analysis of the primary lesion would have missed the 
metastasis-speciﬁ  c ERBB2 mutation. Assuming that this 
mutation acts as a driver, would an ERBB2 inhibitor have 
been clinically eﬀ  ective in this patient?
Abbreviation
SNV = single-nucleotide variant.
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